Navigation Links
GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial
Date:10/30/2007

Overall Survival Results Do Not Achieve Statistical Significance

IRVINE, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc.'s (Nasdaq: SPPI) licensee, GPC Biotech, today announced that the Phase 3 SPARC trial evaluating satraplatin for the treatment of hormone-refractory prostate cancer did not meet its primary efficacy endpoint.

"We are indeed disappointed that the overall survival data for satraplatin did not achieve statistical significance. Drug development is inherently risky and clinical studies do sometimes fail for various reasons, which is why we built Spectrum on a business model based on a diversified portfolio of several late- and early-stage drug candidates. We are not dependent on the success or failure of any one drug," said Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. "We will continue to aggressively develop our four late-stage drugs, ISO-Vorin(TM), which has a January 11th FDA action date; sumatriptan injection, which we will launch with PAR Pharmaceutical Companies in the second-half of 2008; EOquin(R), which is currently enrolling patients in two Phase 3 trials; and ozarelix, where we are currently working on the protocol for the pivotal registrational trial. Furthermore, we are currently planning and/or conducting studies for elsamitrucin, lucanthone, ortataxel, RenaZorb(TM), SPI-1620 and SPI-205."

About Satraplatin

In 2002, Spectrum licensed the global rights to GPC Biotech (Frankfurt Stock Exchange: GPC; TecDAX index; Nasdaq: GPCB). GPC Biotech is responsible for all costs associated with the development and regulatory filings of Satraplatin. GPC Biotech has license agreements with Ph
'/>"/>

SOURCE Spectrum Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Biotechnology industry expected to grow into a three billion dollar industry by 2002
2. Biotechnology on the lead
3. Panacea Biotech To Market Anthrax Vaccine
4. Commercialization of Biotech Discoveries, An Encouragement For Researchers
5. Biotech drug causing anemia-EPREX
6. Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
7. Biologicals Transfer Proposal between US and Indian Biotechnology
8. Finland and India to interact and cooperate in the filed of telemedicine and biotechnology
9. Vical Biotech and NIH jointly develops HIV vaccine
10. Biotechnology Initiatives Planned In Hyderabad
11. Biotech Osiris to go public
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Mike Stoler believes that there is much to ... New York. That’s why he hosts “Building New ... And that’s why he invited Robert Glazer, Chief ... largest single specialty practice in the greater New York ... specialists and sub-specialists service communities throughout New York and ...
(Date:5/24/2013)... 24, 2013 According to a May 15, ... Media Leads to Spikes in Plastic Surgery Requests,” ... growing prevalence of facial plastic surgery and cosmetic ... have become keenly aware of the need to look good ... Facebook, Google and even Skype's video chat feature (Go to ...
(Date:5/24/2013)... 24 (HealthDay News) -- About one in five parents ... take up smoking, drinking or illicit drug use, a ... say experts at the Substance Abuse and Mental Health ... are actually one of the most influential forces helping ... "Surveys of teens repeatedly show that parents can ...
(Date:5/24/2013)... May 2013, Paris, France: Transcatheter aortic valve implantation (TAVI) ... early experience based on first results from a multicentre ... "TAVI has become a treatment option for ... data are virtually all from North American or European ... Heart Center, Singapore, told the conference. He explained that ...
(Date:5/24/2013)... 24, 2013 Fit Yummy Mummy, a ... mothers who are trying to get rid of the ... is ideal for women who want to combine exercises ... ’s Stan Stevenson, prompting an investigative review. , ... contains a wide variety of motivational strategies, nutritional plans, ...
Breaking Medicine News(10 mins):Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 3Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 4Health News:Facebook and Google – Is Social Media Driving Demand for Plastic Surgery? 2Health News:Parents Underestimate Influence Over Teens' Substance Abuse: Survey 2Health News:Registry confirms TAVI efficacy and safety in Asian patients 2Health News:Fit Yummy Mummy: Review Examining Holly Rigsby’s Fitness Program Released 2
... , LOS ANGELES, Aug. 24 The following statement ... Wilentz Goldman & Spitzer, P.A., Reed Smith LLP, and Thompson Hine LLP ... California, for the County of Los Angeles, Central Civil West: , ... For the Purchase of the Hormone Replacement Therapy Drugs Estratest or Estratest ...
... FARMINGTON HILLS, Mich., Aug. 24 Premier Inc. ... contract to provide RFID Asset Tracking and Management Solutions for ... the country, comprised of more than 1,700 hospitals and 49,000 ... purchasing power. , , "We are ...
... , , , ... California had an opportunity to "become senior citizens" on Friday thanks ... SCAN Health Plan. The award-winning program is a workshop that provides ... senior" through a series of hands-on exercises and sensory ...
... EDEN PRAIRIE, Minn., Aug. 24 NovoLogix, ... it has achieved full accreditation with the Healthcare Network ... Commission (EHNAC). EHNAC,s HNAP accreditation recognizes excellence in health ... standards and HIPAA regulations. , , ...
... Diseases (NIAID), a component of the National Institutes of ... to establish a consortium of human immune profiling research ... receive funding up to $100 million over five yearsis ... and to understand how it changes following infection or ...
... popular social networking tool that was at first merely ... and family, is emerging as a potentially valuable means ... alerts, as described in a feature article in the ... Telemedicine and e-Health , a peer-reviewed journal published by ...
Cached Medicine News:Health News:The Rossbacher Law Firm, Hagens Berman Sobol Shapiro LLP, Wilentz Goldman & Spitzer, P.A., Reed Smith LLP and Thompson Hine LLP, Announce the Proposed Settlement of a Class Action Lawsuit Concerning Estratest and Solvay Pharmaceuticals, Inc. 2Health News:The Rossbacher Law Firm, Hagens Berman Sobol Shapiro LLP, Wilentz Goldman & Spitzer, P.A., Reed Smith LLP and Thompson Hine LLP, Announce the Proposed Settlement of a Class Action Lawsuit Concerning Estratest and Solvay Pharmaceuticals, Inc. 3Health News:The Rossbacher Law Firm, Hagens Berman Sobol Shapiro LLP, Wilentz Goldman & Spitzer, P.A., Reed Smith LLP and Thompson Hine LLP, Announce the Proposed Settlement of a Class Action Lawsuit Concerning Estratest and Solvay Pharmaceuticals, Inc. 4Health News:USC Gerontology Students Participate in 'Aging Sensitivity Training' Provided by SCAN Health Plan 2Health News:NovoLogix, Inc. Receives EHNAC Healthcare Network Accreditation 2Health News:NovoLogix, Inc. Receives EHNAC Healthcare Network Accreditation 3Health News:NIAID to fund new human immune profiling research centers 2Health News:Twitter and health care -- can a tweet a day keep the doctor away? 2
(Date:5/23/2013)... BRAINTREE, Mass. , May 23, 2013  Haemonetics Corporation ... Chris Lindop , CFO & EVP-Business Development, will present ... Care Conference in Boston, MA on ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) The public may ... About Haemonetics Haemonetics (NYSE: ...
(Date:5/23/2013)... PAUL, Minn. , May 23, 2013  MGC ... Corporation), a global medical technology company, today scheduled a ... second quarter of fiscal year 2013, ended April 30, ... on Thursday, May 30, 2013. The Company will report ... 2013 after the markets close on Thursday, May 30, ...
(Date:5/23/2013)... , May 23, 2013  Hadasit Bio-Holdings Ltd. ... of biotech companies, based on intellectual property developed ... Israel ,s foremost medical research center, today ... Ltd., received significant funding from the Israeli Ministry ... Scientist (OCS) to support product development and advance ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... April 19, 2011 Cumberland Pharmaceuticals Inc. ... focused on hospital acute care and gastroenterology markets, today ... acquire the rights to ifetroban, a new Phase II ... the brand name Hepatoren™ (ifetroban) Injection and is evaluating ...
... 18, 2011 Two lawsuits were filed today on ... have failed.  The cases were filed on behalf of ... DePuy Orthopaedics, Inc., DePuy Inc., DePuy International, Ltd., Johnson ... Johnson & Johnson International, Inc. John David Hart of ...
Cached Medicine Technology:Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 2Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 3Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 4Recalled DePuy Hip Implant Lawsuits Filed in Fort Worth, Texas 2
1.0 mm Micro System. The Titanium Micro System is also useful in the practice of ENT, Neurosurgery and Handsurgery....
... Codman Sofwire Cable ... bony fixation including sublaminar ... maxillo facial surgery, sternotomy ... cables and a complete ...
Specially designed combination of demineralized bone fibers and demineralized bone cubes that are both osteoinductive and osteoconductive. Packs well into bone defects. Eliminates the need to mix can...
Demineralized bone matrix dispensed in a syringe. DBM will be free of foreign matter. Demineralized bone matrix particle size 125 to 850 . Glycerol 70-88% by weight. Calcium content less than 8%....
Medicine Products: